Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease

Cardiovasc Res. 2001 Feb 1;49(2):281-7. doi: 10.1016/s0008-6363(00)00247-9.
No abstract available

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / immunology
  • Cardiovascular Diseases / metabolism
  • Coronary Vessels
  • Endothelin-1 / biosynthesis
  • Endothelins / biosynthesis
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / metabolism
  • Fibrinolytic Agents / therapeutic use
  • Free Radical Scavengers / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Lovastatin / therapeutic use*
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism
  • Neutrophil Infiltration / drug effects
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type III
  • Protein Precursors / biosynthesis
  • Simvastatin / therapeutic use

Substances

  • Endothelin-1
  • Endothelins
  • Fibrinolytic Agents
  • Free Radical Scavengers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Protein Precursors
  • Nitric Oxide
  • Lovastatin
  • Simvastatin
  • NOS3 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III